Latest Headlines

Latest Headlines

IntelGenx looks to mimic Biovail's success

With its bevy of drug delivery platforms and recent success in Big Pharma partnerships, IntelGenx is looking to duplicate the success of Biovail, CEO Horst Zerbe said.

Canada bars Biovail founder Melnyk from executive office

Biovail founder Eugene Melnyk (photo) will be persona non grata in Canadian public company circles for a while. The Ontario Securities Commission (OSC), Canada's securities regulator, barred Melnyk

Court rules in IntelGenx's favor in Wellbutrin-maker's lawsuit

Quebec-based IntelGenx received a positive ruling Tuesday in a case involving two patents owned by Biovail Laboratories, the maker of the antidepressant Wellbutrin XL. The U.S. District Court of

In wake of chairman's exit, Valeant CFO resigns

'Tis the time of year for executive turmoil, apparently. Valeant Pharmaceuticals ($VRX) CFO Peggy Mulligan resigned abruptly, just a week after Chairman Bill Wells departed. This means the company is

Lawmakers object to Biovail-Valeant merger

Maybe the soon-to-merge Valeant Pharmaceuticals and Biovail shouldn't have talked so openly about plans to lay off a big chunk of the combined workforce. On the eve of a shareholder vote to approve

Good news: Merck to add 310 jobs; bad news: Biovail/Valeant to cut 1,100

It promised North Carolina 440 jobs in two years to meet increased demand for its vaccines. Merck now says it will add 310 more. "We have grown much faster than anyone had anticipated," says plant

Shionogi cutting 350 reps as Biovail boosts layoffs

We've got news for those of you keeping tabs on pharma layoffs. Not only have Valeant and Biovail announced that their planned post-merger job cuts will amount to 25 percent of the combined

Biovail brings drug delivery tech in Valeant merger

Earlier this week, Biovail and Valeant Pharmaceuticals pulled the wraps of a deal to merge the two companies into a much larger, more diversified operation that will combine pipelines for CNS drugs

Biovail-Valeant combo to claim up to 870 jobs

Yesterday's press release about the Biovail-Valeant Pharmaceuticals merger didn't mention one key fact: Combining the two companies will lead to layoffs. Up to 20 percent of the combined

Biovail, Valeant hatch $3.2B reverse merger

The Biovail (NYSE/TSX: BVF) name will soon be no more if a reverse merger with Valeant Pharmaceuticals (NYSE: VRX) goes through as planned. And not only would the $3.2 billion cash-and-stock deal